vs
多邻国（DUOL）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
多邻国的季度营收约是Orthofix Medical Inc.的1.3倍（$282.9M vs $219.9M），多邻国净利率更高（14.8% vs -1.0%，领先15.8%），多邻国同比增速更快（35.0% vs 2.0%），多邻国自由现金流更多（$96.6M vs $16.8M），过去两年多邻国的营收复合增速更高（29.9% vs 8.0%）
多邻国是全球知名教育科技企业，提供覆盖40余种语言的免费及付费游戏化自适应学习课程，同时推出官方语言能力认证、数学学习、扫盲教育等服务，面向个人用户、教育机构及企业客户提供多元学习解决方案。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
DUOL vs OFIX — 直观对比
营收规模更大
DUOL
是对方的1.3倍
$219.9M
营收增速更快
DUOL
高出33.0%
2.0%
净利率更高
DUOL
高出15.8%
-1.0%
自由现金流更多
DUOL
多$79.7M
$16.8M
两年增速更快
DUOL
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $282.9M | $219.9M |
| 净利润 | $42.0M | $-2.2M |
| 毛利率 | 72.8% | 71.1% |
| 营业利润率 | 15.4% | 0.2% |
| 净利率 | 14.8% | -1.0% |
| 营收同比 | 35.0% | 2.0% |
| 净利润同比 | 201.7% | 92.4% |
| 每股收益（稀释后） | $0.99 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DUOLOFIX
| Q4 25 | $282.9M | $219.9M | ||
| Q3 25 | $271.7M | $205.6M | ||
| Q2 25 | $252.3M | $203.1M | ||
| Q1 25 | $230.7M | $193.6M | ||
| Q4 24 | $209.6M | $215.7M | ||
| Q3 24 | $192.6M | $196.6M | ||
| Q2 24 | $178.3M | $198.6M | ||
| Q1 24 | $167.6M | $188.6M |
净利润DUOLOFIX
| Q4 25 | $42.0M | $-2.2M | ||
| Q3 25 | $292.2M | $-22.8M | ||
| Q2 25 | $44.8M | $-14.1M | ||
| Q1 25 | $35.1M | $-53.1M | ||
| Q4 24 | $13.9M | $-29.1M | ||
| Q3 24 | $23.4M | $-27.4M | ||
| Q2 24 | $24.4M | $-33.4M | ||
| Q1 24 | $27.0M | $-36.0M |
毛利率DUOLOFIX
| Q4 25 | 72.8% | 71.1% | ||
| Q3 25 | 72.5% | 72.2% | ||
| Q2 25 | 72.4% | 68.7% | ||
| Q1 25 | 71.1% | 62.8% | ||
| Q4 24 | 71.9% | 69.0% | ||
| Q3 24 | 72.9% | 68.7% | ||
| Q2 24 | 73.4% | 67.8% | ||
| Q1 24 | 73.0% | 67.5% |
营业利润率DUOLOFIX
| Q4 25 | 15.4% | 0.2% | ||
| Q3 25 | 12.9% | -8.3% | ||
| Q2 25 | 13.2% | -7.9% | ||
| Q1 25 | 10.2% | -25.2% | ||
| Q4 24 | 6.6% | -5.3% | ||
| Q3 24 | 7.0% | -9.6% | ||
| Q2 24 | 10.5% | -12.5% | ||
| Q1 24 | 9.8% | -15.6% |
净利率DUOLOFIX
| Q4 25 | 14.8% | -1.0% | ||
| Q3 25 | 107.5% | -11.1% | ||
| Q2 25 | 17.8% | -6.9% | ||
| Q1 25 | 15.2% | -27.4% | ||
| Q4 24 | 6.6% | -13.5% | ||
| Q3 24 | 12.1% | -13.9% | ||
| Q2 24 | 13.7% | -16.8% | ||
| Q1 24 | 16.1% | -19.1% |
每股收益（稀释后）DUOLOFIX
| Q4 25 | $0.99 | $-0.05 | ||
| Q3 25 | $5.95 | $-0.57 | ||
| Q2 25 | $0.91 | $-0.36 | ||
| Q1 25 | $0.72 | $-1.35 | ||
| Q4 24 | $0.31 | $-0.76 | ||
| Q3 24 | $0.49 | $-0.71 | ||
| Q2 24 | $0.51 | $-0.88 | ||
| Q1 24 | $0.57 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $450.0M |
| 总资产 | $2.0B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DUOLOFIX
| Q4 25 | $1.0B | $82.0M | ||
| Q3 25 | $1.0B | $62.9M | ||
| Q2 25 | $976.2M | $65.6M | ||
| Q1 25 | $884.0M | $58.0M | ||
| Q4 24 | $785.8M | $83.2M | ||
| Q3 24 | $854.4M | $30.1M | ||
| Q2 24 | $888.2M | $26.4M | ||
| Q1 24 | $829.7M | $27.0M |
总债务DUOLOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益DUOLOFIX
| Q4 25 | $1.3B | $450.0M | ||
| Q3 25 | $1.3B | $442.5M | ||
| Q2 25 | $977.0M | $458.3M | ||
| Q1 25 | $893.8M | $458.3M | ||
| Q4 24 | $824.5M | $503.1M | ||
| Q3 24 | $822.5M | $525.9M | ||
| Q2 24 | $766.9M | $546.0M | ||
| Q1 24 | $711.1M | $570.3M |
总资产DUOLOFIX
| Q4 25 | $2.0B | $850.6M | ||
| Q3 25 | $1.9B | $832.6M | ||
| Q2 25 | $1.5B | $837.2M | ||
| Q1 25 | $1.4B | $823.1M | ||
| Q4 24 | $1.3B | $893.3M | ||
| Q3 24 | $1.2B | $867.9M | ||
| Q2 24 | $1.1B | $882.0M | ||
| Q1 24 | $1.1B | $906.0M |
负债/权益比DUOLOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $107.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $96.6M | $16.8M |
| 自由现金流率自由现金流/营收 | 34.1% | 7.6% |
| 资本支出强度资本支出/营收 | 3.8% | 4.9% |
| 现金转化率经营现金流/净利润 | 2.56× | — |
| 过去12个月自由现金流最近4个季度 | $369.7M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流DUOLOFIX
| Q4 25 | $107.3M | $27.7M | ||
| Q3 25 | $84.2M | $12.4M | ||
| Q2 25 | $90.7M | $11.6M | ||
| Q1 25 | $105.6M | $-18.4M | ||
| Q4 24 | $83.3M | $23.7M | ||
| Q3 24 | $56.3M | $11.7M | ||
| Q2 24 | $62.4M | $9.0M | ||
| Q1 24 | $83.5M | $-18.6M |
自由现金流DUOLOFIX
| Q4 25 | $96.6M | $16.8M | ||
| Q3 25 | $79.4M | $2.5M | ||
| Q2 25 | $89.5M | $4.5M | ||
| Q1 25 | $104.3M | $-25.1M | ||
| Q4 24 | $81.4M | $15.2M | ||
| Q3 24 | $53.1M | $6.3M | ||
| Q2 24 | $56.8M | $-360.0K | ||
| Q1 24 | $82.1M | $-29.1M |
自由现金流率DUOLOFIX
| Q4 25 | 34.1% | 7.6% | ||
| Q3 25 | 29.2% | 1.2% | ||
| Q2 25 | 35.5% | 2.2% | ||
| Q1 25 | 45.2% | -13.0% | ||
| Q4 24 | 38.8% | 7.0% | ||
| Q3 24 | 27.6% | 3.2% | ||
| Q2 24 | 31.9% | -0.2% | ||
| Q1 24 | 49.0% | -15.4% |
资本支出强度DUOLOFIX
| Q4 25 | 3.8% | 4.9% | ||
| Q3 25 | 1.8% | 4.8% | ||
| Q2 25 | 0.5% | 3.5% | ||
| Q1 25 | 0.6% | 3.5% | ||
| Q4 24 | 0.9% | 4.0% | ||
| Q3 24 | 1.7% | 2.7% | ||
| Q2 24 | 3.1% | 4.7% | ||
| Q1 24 | 0.8% | 5.6% |
现金转化率DUOLOFIX
| Q4 25 | 2.56× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 2.02× | — | ||
| Q1 25 | 3.01× | — | ||
| Q4 24 | 5.99× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 2.56× | — | ||
| Q1 24 | 3.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DUOL
| License And Service | $242.3M | 86% |
| Advertising | $20.2M | 7% |
| English Test | $10.3M | 4% |
| Other | $10.1M | 4% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
